LeongGuan
2021-07-20
[得意]
[得意]
T2 Biosystems Reports Granting of Inducement Award
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":178060127,"tweetId":"178060127","gmtCreate":1626772691369,"gmtModify":1631891617421,"author":{"id":3569573964815197,"idStr":"3569573964815197","authorId":3569573964815197,"authorIdStr":"3569573964815197","name":"LeongGuan","avatar":"https://static.tigerbbs.com/22e6d2e01acf853f12b4eae3a1ea9c1b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[得意] </span><span>[得意] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[得意] </span><span>[得意] </span></p></body></html>","text":"[得意] [得意]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/178060127","repostId":2152665229,"repostType":2,"repost":{"id":"2152665229","pubTimestamp":1626728340,"share":"https://www.laohu8.com/m/news/2152665229?lang=&edition=full","pubTime":"2021-07-20 04:59","market":"us","language":"en","title":"T2 Biosystems Reports Granting of Inducement Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2152665229","media":"GlobeNewswire","summary":"LEXINGTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in th","content":"<html><body><p>LEXINGTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/TTOO\">T2 Biosystems</a>, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eleven new employees.<br/></p>\n<p>The awards were made on July 8, 2021 under T2 Biosystems’ Inducement Award Plan (the \"Inducement Plan\"), which was adopted on March 1, 2018 and amended and restated on January 8, 2020 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of options to purchase 321,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options was $1.06 which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on July 8, 2021. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).</p>\n<p><strong>About T2 Biosystems:</strong></p>\n<p>T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx<sup>®</sup> Instrument, T2Candida<sup>®</sup> Panel, the T2Bacteria<sup>®</sup> Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR<sup>®</sup>) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.</p>\n<p><strong>Media Contact:</strong><br/>Gina Kent, Vault Communications<br/>gkent@vaultcommunications.com <br/>610-455-2763</p>\n<p><strong>Investor Contact:</strong><br/>Philip Trip Taylor, Gilmartin Group<br/>philip@gilmartinIR.com <br/>415-937-5406</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/8b2f8184-6fd4-40b4-88fa-90aa15d5e3df\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>T2 Biosystems Reports Granting of Inducement Award</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nT2 Biosystems Reports Granting of Inducement Award\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 04:59 GMT+8 <a href=https://finance.yahoo.com/news/t2-biosystems-reports-granting-inducement-205900646.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LEXINGTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/t2-biosystems-reports-granting-inducement-205900646.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/5ztomAU2Mnok1wFhAWQgYA--~B/aD0yMjg7dz02NjM7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/gqLkKq0wMc6z5nIcpfiJQw--~B/aD0yMjg7dz02NjM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76ea202e662dd8e06f1c612524529829","relate_stocks":{"TTOO":"T2 Biosystems"},"source_url":"https://finance.yahoo.com/news/t2-biosystems-reports-granting-inducement-205900646.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2152665229","content_text":"LEXINGTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eleven new employees.\nThe awards were made on July 8, 2021 under T2 Biosystems’ Inducement Award Plan (the \"Inducement Plan\"), which was adopted on March 1, 2018 and amended and restated on January 8, 2020 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of options to purchase 321,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options was $1.06 which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on July 8, 2021. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).\nAbout T2 Biosystems:\nT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.\nMedia Contact:Gina Kent, Vault Communicationsgkent@vaultcommunications.com 610-455-2763\nInvestor Contact:Philip Trip Taylor, Gilmartin Groupphilip@gilmartinIR.com 415-937-5406","news_type":1},"isVote":1,"tweetType":1,"viewCount":667,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/178060127"}
精彩评论